New 52-week peak reached by Haemonetics shares: What’s driving the surge?

HAE · Haemonetics Corporation

The AI's read

Haemonetics struck a supply agreement with CSL Plasma to roll NexSys PCS and Persona PLUS across U.S. centers. The deal is non-exclusive, has no minimums, and management left fiscal 2027 guidance unchanged. The market already reacted hard — shares jumped ~16.8% to a new 52-week high and RSI sits at 76.42, so price looks stretched. BTIG bumped its price target to $110, but the implementation schedule and financial impact are unresolved until November. We don't see confirmed orders or guidance changes that justify the rally settling as durable upside. We lean neutral until Haemonetics provides rollout scope, volumes, or any revenue timing clarity.